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Humans are exposed to polycyclic aromatic hydrocarbons (PAHs) from various occupational,
environmental, medicinal, and dietary sources. PAH metabolites in human urine can be used as
biomarkers of internal dose to assess recent exposure to PAHs. PAH metabolites that have been
detected in human urine include 1-hydroxypyrene (1-OHP), 1-hydroxypyrene-O-glucuronide
(1-OHP-gluc), 3-hydroxybenzo[alpyrene, 7,8,9,1 0-tetrahydroxy-7,8,9, 10-tetrahydrobenzo[alpyrene,
and a number of other hydroxylated PAHs. The most widely used of these is l-OHP-gluc, the
major form of 1-OHP in human urine, by virtue of its relatively high concentration and prevalence
in urine and its ease of measurement. This metabolite of pyrene can be measured as 1-OHP after
deconjugation of the glucuronide with P-glucuronidase or directly as 1-OHP-gluc without
deconjugation. Elevated levels of 1-OHP or 1-OHP-gluc have been demonstrated in smokers
(versus nonsmokers), in patients receiving coal tar treatment (versus pretreatment), after
workshifts in road pavers (versus before shifts or versus controls), after shifts in coke oven work-
ers (versus before shift), and in subjects ingesting charbroiled meat (versus preingestion). More
importantly, this metabolite is found (at low levels) in most human urine, even in persons without
apparent occupational or smoking exposure. Although measurement of these metabolites is
useful in assessing recent exposure to PAHs, their value as predictive markers of biological
effect or health outcomes has not been rigorously tested and at present can only be inferred by
association. Environ Health Perspect 104(Suppl 5):927-932 (1996)
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Introduction
Polycyclic aromatic hydrocarbons (PAHs)
are produced during incomplete combus-
tion of organic materials, and some are
known to be carcinogenic or cocarcino-
genic. Humans may be exposed to these
compounds from a wide variety ofsources,
including occupation (coke oven or iron
foundry workers), environment (air pollu-
tants, drinking water), personal habits
(e.g., smoking), medical treatment (coal
tar), and diet (broiled and smoked foods)
(1-8). PAHs are readily absorbed into
the body through the skin, lungs, and
gastrointestinal tract. Exposure to PAHs
has been associated with lung and skin
cancer in occupational settings and may be
associated with other human cancers
(9-13). In addition to their carcinogenic
properties, PAHs are known to induce
metabolic enzymes and are cytotoxic.
The measurement of PAH metabolites
in urine has been proposed as a means of
assessing recent exposure to these com-
pounds. Besides the general advantages of
urinary markers such as noninvasiveness
and ready accessibility, urinary PAH
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metabolites are useful when assessing
multiple routes ofexposure, when assessing
external exposure is difficult, or when col-
lecting blood is unacceptable. The mea-
surement of carcinogen metabolites in
urine has several potential uses: a) identi-
fication ofgroups and/or individuals with
recent exposure and, as a result, possibly
elevated risk of adverse health effects;
b) improvement of exposure information
in general and examination of geographic
or household differences; c) improvement
of risk extrapolation between species; and
d) understanding the etiology of and sus-
ceptibility to human carcinogenesis. For
urinary PAH biomarkers to be validated
for wide application in human popula-
tions, a number of relevant factors should
be examined: inter- and intraindividual
variation, sensitivity and specificity of the
measuring methods, and knowledge about
the kinetics of occurrence and persistence
ofthe biomarker (14).
Urinary PAH Metabolites as
Biomarkers of Internal Dose
PAH Metabolites Detected
A number of urinary markers ofexposure
to PAHs have been investigated to assess
recent exposure to these compounds.
Becher and Bj0rseth (15) developed an
analytical procedure to measure PAHs in
human urine by chemically reducing the
metabolites to parent PAHs and subse-
quent analysis by HPLC with fluorescence
detection. Although this approach increases
the sensitivity ofthe assay by increasing the
amount of parent compound used in the
analysis, a considerable body of informa-
tion about individual metabolites (and
their ratios) is lost in this process. The
recovery of the assay varied between 10
and 85% depending on the individual
compound, and the amount ofcompound
detected increased about 5-fold after reduc-
tion of metabolites. Using this methodol-
ogy, 11 urinary PAHs were quantitated in
aluminum plant workers and controls
stratified by smoking status (16). Total
PAH levels were elevated in occupationally
exposed workers and current smokers com-
pared to nonsmoking controls; however,
when some individual PAHs, including
benzo[a]pyrene (B[a]P), were examined,
no differences were observed. In addition,
the assay was not sensitive enough to
examine the relationship between the air
concentration of PAHs and the excretion
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of PAHs in human urine. Further applica-
tion of this method (reversed metabolism)
to urine samples from workers in alu-
minum plants in Italy (17) and from coke
oven workers (18) did not show differences
in PAH levels in urine between exposed
workers and nonexposed controls.
Keimig et al. (19) reported that
1-hydroxypyrene (1-OHP) is a major
metabolite of pyrene in pig urine using
high performance liquid chromatography
(HPLC) with fluorescence detection and
gas chromatography-mass spectrometry
(GC-MS) confirmation. Jongeneelen et al.
(20-24) subsequently performed a series of
studies evaluating the excretion of PAH
metabolites in rodent and human urine.
They also measured 3-hydroxybenzo-
[a]pyrene (3-OH-B[a]P) in rat urine by
HPLC analysis after oral administration of
B[a]P given in different dose levels (25).
Because the urinary concentration of
3-OH-B[a]P was 2500-fold lower than
that of 1-OHP in psoriatic patients under-
going dermal coal tar treatment, these
investigators suggested that measurement
of 1-OHP in urine by HPLC would be a
more sensitive assay to monitor occupa-
tional exposure to PAHs (22). A number
of studies were conducted to measure
1-OHP in urine of individuals exposed to
PAHs occupationally and therapeutically.
These included coke oven workers, petro-
leum coke handlers, operators of a creo-
sote-impregnating plant, psoriatic patients
treated with mineral coal tar, and eczema-
tous dermatitis patients undergoing coal
tar ointment treatment. Although some
specific PAH metabolites were identified in
urine after exposure to PAHs, it was
impossible to characterize all ofthe isolated
metabolites. Some of these might be more
important than 1-OHP as biomarkers of
exposure to PAHs in terms ofhealth effects
and biological relevance (20,23,24,26).
In a recent study (27), pyrene metabo-
lites were measured in human urine before
enzymatic deconjugation. The analytical
method used immunoaffinity chromatog-
raphy (IAC) using anti-PAH adduct anti-
body, HPLC with fluorescence detection,
and the complementary techniques ofsyn-
chronous fluorescence spectroscopy (SFS)
and GC-MS to measure pyrene-containing
metabolites. The majority of urinary
1-hydroxypyrene was conjugated to glu-
curonide. Because 1-hydroxypyrene-glu-
curonide is approximately 5-fold more
fluorescent than 1-OHP, it provides a
more sensitive biomarker for assessing
exposure to pyrene.
Gomes and Santella (28) investigated
methods for the detection of B[a]P
metabolites in rodent urine by applying
several different preparative methods (ethyl
acetate extraction, Sep-pak C18 cartridge
chromatography, XAD-2 resin chromatog-
raphy, and IAC using anti-PAH adduct
antibody) and quantitation of metabolites
by competitive enzyme-linked immunosor-
bent assay (ELISA). They concluded that
metabolites are isolated best (52% recov-
ery) by IAC. Because the monoclonal
antibodies used to prepare their immuno-
affinity columns and used in their ELISAs
showed cross-reactivity with other B[a]P
and PAH metabolites, they suggested
that this assay may be useful as a general
indicator ofexposure to PAHs.
More recently, Weston et al. (29)
reported an assay for quantitation of
B[a]P-tetrol in human urine by sequential
use of several analytical methods, IAC,
HPLC, and SFS. Although the sensitivity
of the assay was good (limit of detection
was 0.01 pmol/ml urine for a 10-ml urine
sample), the overall recovery of the assay
(about 30%) could be improved to enhance
the sensitivity of the assay. In spite of the
low recovery rate ofthe assay, 0.24 to 3.12
pmol B[a]P-tetrol/ml urine was detected in
four individuals who had recently consumed
charbroiled beef.
Further application of HPLC and
GC-MS methodologies [(30); S Myers,
unpublished data] have identified addi-
tional hydroxylated and methylated PAHs
in human urine. Ofparticular interest are
the methylated PAH metabolites, which
have not been studied in great detail but
are highly mutagenic.
Association ofPAHMetaboliteLevels
with PAH Exposure in HumanStudies
Levels of 1-OHP in urine from individuals
exposed to several different PAH sources
are summarized in Table 1. Elevated levels
of 1-OHP have been demonstrated in
smokers, in patients after coal tar treatment,
after workshifts in road pavers, after shifts
in coke oven workers, after shifts in alu-
minum reduction workers, and in subjects
ingesting charbroiled meat (20-24,31-35).
These results indicate that considerable
variability occurs in these measurements
when performed by different investigators
at different worksites. Identifying the
relative contribution of several potential
sources of variability (e.g., laboratory,
exposure, or biological differences) is the
focus of much of the current research in
this area.
KineticsandInterindividualVariation
inMetaboliteExcretion
An understanding ofthe excretion kinetics
of PAH metabolites is necessary for their
effective use as indicators of exposure.
Studies in occupationally exposed workers
suggest that the half-life for urinary excre-
tion of 1-OHP is about 18 hr (36) and
ranges from 6 to 35 hr (24). Significant
differences in preshift and postshift
concentrations of urinary 1-OHP are
consistent with overnight (16 hr) clearance
of the internal dose ofpyrene received on
the previous day (31). The major routes
of occupational exposure to pyrene in
these groups are through inhalation and
cutaneous absorption.
Additional information on excretion
kinetics is obtained from PAH ingestion
studies. Urinary excretion ofPAH metabo-
lites has been examined in several con-
trolled feeding protocols (34,35,37). The
kinetics of 1-OHP excretion was examined
during and after ingestion of broiled beef
containing PAHs (34). Ingestion of 250 g
ofbroiled meat resulted in a 4- to 12-fold
increase in urinary 1-OHP concentration.
Maximum excretion occurred at approxi-
mately 6.3 hr after ingestion and declined
thereafter with an estimated half-life of4.4
hr. Thus, most of the 1-OHP would be
excreted within about 15 hr (two half-lives
after maximum). In another charbroiled
beef feeding study (35), urinary 1-OHP
was markedly elevated within 16 to 20 hr
of ingestion and remained marginally
elevated (2.5-fold above prefeed baseline)
72 hr after ingestion.
Biologically determined interindividual
variation is difficult to assess in occupa-
tional exposure settings because of the
uncertainty of true exposure and dose.
However, controlled feeding studies allow
a comparison of internal dose biomarkers
with virtually identical exposures because
food can be centrally prepared, homoge-
nized, and weighed. Under such conditions
(35), interindividual variation (8-fold) was
observed among 10 subjects ingesting iden-
tical quantities ofcharbroiled beef. Thus,
major individual differences in absorption,
metabolism, and/or excretion of pyrene
are indicated.
Use of PAH Metabolites
in the Study of Biological
Effect and Risk Assessment
AnimalStudies
In animal models, the majority ofpyrene is
excreted in the urine and bile as glucuronide
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Table 1. Levels of 1-hydroxypyrene in human urine.
1-Hydroxypyrene,
Group n pmol/mol creatinine (range) Reference
Nonsmokers 14 0.17 (0.01-0.93) (24)
Smokers 28 0.51 (0.04-1.24)
Asphalt pavers (23)
Preshift 43 1.35
Postshift 43 1.76
Aluminum plantworkers (31)
Control 46 (0.44-0.61)
Preshift 55 (0.43-0.77)
Postshift 55 (1.93-3.60)
Coke oven workers (24)
Preshift 44 0.89 (0.24-3.50)
Postshift 44 2.47 (0.46-11.2)
Foundry workers (32)
Nonsmokers
Controls 20 0.16 (0.01-0.22)
Exposed 16 0.11 (0.09-0.13)
Smokers
Controls 26 0.26 (0.18-0.34)
Exposed 20 0.42 (0.25-0.59)
Steel plantworkersa (33)
Nonsmokers
Low PAH 20 0.05
Mid-PAH 15 0.15
High PAH 5 0.37 (0.02-0.89)
Smokers
Low PAH 20 0.06
Mid-PAH 12 0.19
High PAH 12 0.82 (0.15-3.57)
Coal tar patients (20,22)
Pretreatment 4 (1-20)
Posttreatment 4 (100-500)
PAH in diet (34)
Preconsumption 5 0.09 (0.01-0.58)
Postconsumption 5 1.51 (0.80-2.01)
PAHs in dieta (35)
Preconsumption 10 0.02 (0.01-0.14)
Postconsumption 10 0.38 (0.08-1.10)
PAHs, polycyclic aromatic hydrocarbons. "Measured as 1-hydroxypyrene-glucuronide.
or sulfate conjugates of hydroxylated
pyrene metabolites (e.g., 1-OHP, 1,6-dihy-
drodiolpyrene, or 1,8-dihydrodiolpyrene)
(38). The primary route of excretion of
higher molecular weight PAHs (e.g.,
B[a]P) is via the feces (10), with only
about 1 to 3% ofB[a]P dose administered
being recovered as urinary metabolites in
rats (39,40) or 12% as urinary metabolites
in rabbits (41).
Camus et al. (42) compared urinary
B[a]P metabolite concentrations in two
strains of mice with different susceptibility
to PAH-induced carcinogenesis due to
their different capacities to metabolize and
activate PAHs. The more susceptible strain
excreted more 3-OH-B[a]P than the resis-
tant strain, consistent with the more rapid
metabolism in the susceptible strain.
However, less than 0.1% of the adminis-
tered dose was detected as 3-OH-B[a]P in
the urine. Similarly, Jongeneelen et al. (43)
reported that cumulative excretion of
3-OH-B[a]P in rat urine was only 0.22 to
0.35% of administered dose after three
consecutive high doses ofB[a]P, or 0.11 to
2.3% of administered dose after one
relatively low dose.
Further studies are required to assess
the value ofurinary PAH metabolite levels
as potential indicators of risk as well as
exposure. Likhachev et al. (44) suggested
examining ratios of B[a]P metabolites in
the activation versus deactivation pathways
of B[a]P. For example, they monitored
excretion of 7,8-diol-B[a]P and 3-OH-
B[a]P in urine and feces ofrats in an effort
to predict individual tumor risk.
AssociationofPAHMetabolites
with PAH-DNAAdducts in Humans
A limited number of studies in humans
have examined the association between uri-
nary biomarkers ofPAH internal dose and
biomarkers ofmacro-molecular dose (DNA
adducts). In foundry workers, increasing
levels ofurinary 1-OHP (r=0.27, p=0.07
for trend) or peripheral blood PAH-DNA
adducts (r =0.28, p= 0.08) were observed
with increasing external exposure (45).
However, the correlation coefficient
between the two biomarkers was only 0.15
(p=0.37, n =38). In contrast, the correla-
tion between these two biomarkers in a
study of aluminum plant workers was
highly significant (r= 0.66, p<0.001,
n = 23) for smokers and marginally signi-
ficant (r=0.25, p<0.089, n=31) for non-
smokers (46). In a smaller study ofdietary
exposure to PAHs (35), these two bio-
markers were also significantly correlated
(r = 0.79, p< 0.01). The different results
observed in these studies may be due to
differences in the period of collection of
urine samples in the studies.
RiskAssessment
Assessment of human disease risk associ-
ated with specific agents is based primarily
on data from animal studies. Extrapolation
ofdisease risk between species necessitates
an assumption ofcomparable potency for a
given dose. One approach toward address-
ing this assumption at the molecular level
involves the use of target organ molecular
damage (carcinogen-DNA adduct levels in
the case of cancer) for predicting disease
outcome (47). Although this methodology
has been used to improve exposure assess-
ment in epidemiological studies, more infor-
mation is needed to judge its usefulness in
predicting cancer risk across species
Biological monitoring in the workplace
is useful for evaluating individual exposure;
however, the dose-response relationship
for adverse health effects due to that expo-
sure is rarely known. Estimates of group
disease risk associated with exposure can be
approximated from urinary markers of
internal dose and air measurements of
external exposure in occupations with high
disease prevalence. This approach was used
by Jongeneelen (48) in an attempt to esti-
mate a biological exposure limit value for
urinary l-OHP based on the airborne
threshold limit value of coal tar pitch
volatiles. In a study of PAH exposure in
coke oven workers, measurements of uri-
nary 1-OHP and PAH in personal air sam-
ples were used to construct an empirical
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mathematical relationship between the
two variables. Applying relative risk esti-
mates of lung cancer for topside versus
non-topside coke oven workers, it was pos-
sible to establish an indirect relationship
between lung cancer mortality risk and uri-
nary 1-OHP concentration (48) for coke
oven workers. (It should be noted that this
relationship would be expected to be differ-
ent for other routes ofexposure, other mix-
tures ofPAHs, and other sources ofPAHs.)
Ultimately, validation of these results will
require prospective studies ofdisease risk.
Conclusions
Relevance forlarge-scale
Population Monitoring
Biomonitoring is commonly performed
using either urine or blood samples. The
use of urine has advantages in that it is
obtainable in large quantities, at multiple
time points, and by selfcollection. In some
circumstances, blood collection may not be
medically or culturally acceptable. Depend-
ing on the assay to be performed, urine
samples usually do not require processing
before being frozen. In some cases, solid-
phase extraction ofbiomarkers from urine
before shipment and analysis may be con-
venient (49). In all cases, the stability of
the metabolites of interest under planned
storage and shipping conditions must be
evaluated. A potential disadvantage of
urine biomarkers is that, in general, they
reflect only recent exposure (e.g., within
24-72 hr). However, multiple sampling
can be used to address this issue.
Such biomarkers provide an alternative
approach to improve assessment of expo-
sure in experimental and epidemiologic
studies. This approach has several potential
applications: a) to supplement and refine
exposure information obtained by ques-
tionnaire or records, particularly when
multiple sources of exposure are present,
b) in prospective population studies where
biological samples are banked for later
analysis, c) in case-control studies where
exposure conditions are not affected by
outcome, and d) in prevention studies
where intermediate markers of dose or
effect provide early indicators of change.
These types of studies should ultimately
lead to more accurate risk assessment and
risk identification.
NeedforValidation inTransitional
and Prospective Studies
The use of biomarkers in epidemiologic
studies to enhance exposure assessment,
explore disease mechanism, and assess
acquired and inherited susceptibility
encompasses several objectives and study
designs. These activities are often cate-
gorized as laboratory, transitional, etio-
logic, and public health applications (50).
Optimal use of specific biomarkers (or
classes ofbiomarkers) requires careful con-
sideration ofthe objectives to be addressed
and the appropriate study design. A useful
discussion of this issue and a biomarker-
study design matrix are presented by
Rothman et al. (50). The advantages,
disadvantages, and logistical characteris-
tics of the proposed biomarker should be
considered in planning the study.
Ongoing validation studies are assessing
the usefulness of various biomarkers as
indicators of carcinogen exposure, effect,
and risk. One of the first rigorous tests of
DNA adduct concentration as a predictor
ofhuman cancer risk was reported by Ross
et al. (51,52). They examined the associa-
tion between aflatoxin BI-guanosine
adduct level in urine and subsequent risk
of liver cancer in a nested case-control
design. Aflatoxin adducts and metabolites
were assayed in previously collected and
banked urine samples from liver cancer
cases and matched controls. Detectable
levels of the aflatoxin adducts and several
other aflatoxin metabolites in urine were
predictive ofliver cancer development. In
addition, evidence for a strong interactive
effect between urinary aflatoxin biomarkers
and hepatitis B virus was observed for liver
cancer risk. This study demonstrates the
potential value of using a biomarker of
internal or molecular dose as a predictor of
biological effect and health outcome. As
biomarkers for other compounds are vali-
dated, they will enhance the options avail-
able to epidemiologists in designing studies
to understand and prevent human disease.
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